Frontier
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. May 15, 2022; 13(5): 387-407
Published online May 15, 2022. doi: 10.4239/wjd.v13.i5.387
Role of cannabinoids and the endocannabinoid system in modulation of diabetic cardiomyopathy
Mona F El-Azab, Ahmed E Wakiel, Yossef K Nafea, Mahmoud E Youssef
Mona F El-Azab, Ahmed E Wakiel, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt
Yossef K Nafea, Program of Biochemistry, McMaster University, Hamilton L8S 4L8, Ontario, Canada
Mahmoud E Youssef, Department of Pharmacology and Biochemistry, Delta University for Science and Technology, Mansoura 35511, New Cairo, Egypt
Author contributions: El-Azab MF was responsible for conceptualization and supervision; El-Azab MF and Wakiel AE were responsible for original draft preparation; El-Azab MF, Nafea YK and Youssef ME were responsible for review of the literature and visualization; all authors contributed to the final draft of the manuscript, have read and agreed to the published version of the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mona F El-Azab, PhD, Professor, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Kilo 4.5 Ring Road, Ismailia 41522, Egypt. mona_elazab@pharm.suez.edu.eg
Received: May 31, 2021
Peer-review started: May 31, 2021
First decision: July 3, 2021
Revised: July 18, 2021
Accepted: April 28, 2022
Article in press: April 28, 2022
Published online: May 15, 2022
Processing time: 346 Days and 20.6 Hours
Core Tip

Core Tip: Diabetic cardiomyopathy is considered to be one of the most common deleterious diabetic complications being the leading cause of mortality among diabetic patients. The endocannabinoid system has been implicated in the pathogenesis of diabetes and its complications. However, the role of the endocannabinoid system in diabetic cardiomyopathy has not been fully investigated. This review aims to elucidate the possible mechanisms through which cannabinoids and the endocannabinoid system could interact with the pathogenesis of diabetic cardiomyopathy. Better understanding of the role of cannabinoids and the endocannabinoid system in diabetic cardiomyopathy may provide novel strategies to manipulate this serious diabetic complication.